162 related articles for article (PubMed ID: 38052548)
21. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
[TBL] [Abstract][Full Text] [Related]
22. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
[TBL] [Abstract][Full Text] [Related]
24. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
Hu A; Tang K; Liu J; Han X; Chen Q
Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
[TBL] [Abstract][Full Text] [Related]
25. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
26. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
[TBL] [Abstract][Full Text] [Related]
27. MiR-195-3p is a Novel Prognostic Biomarker Associated with Immune Infiltrates of Lung Adenocarcinoma.
Lao Y; Li T; Xie X; Chen K; Li M; Huang L
Int J Gen Med; 2022; 15():191-203. PubMed ID: 35023957
[TBL] [Abstract][Full Text] [Related]
28. Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
Aizemaiti R; Wu Z; Tang J; Yan H; Lv X
Int J Med Sci; 2021; 18(2):448-458. PubMed ID: 33390814
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
30. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
31. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
32. The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma.
Luo D; Fang M; Shao L; Wang J; Liang Y; Chen M; Gui X; Yan J; Wang W; Yu L; Fan X; Wu Q
Front Biosci (Landmark Ed); 2023 Oct; 28(10):271. PubMed ID: 37919050
[TBL] [Abstract][Full Text] [Related]
33.
Wang FM; Xu LQ; Zhang ZC; Guo Q; Du ZP; Lei Y; Han X; Wu CY; Zhao F; Chen JL
Aging (Albany NY); 2024 Jan; 16(2):1605-1619. PubMed ID: 38244585
[TBL] [Abstract][Full Text] [Related]
34. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F
Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021
[TBL] [Abstract][Full Text] [Related]
35. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
36. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
38. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
[TBL] [Abstract][Full Text] [Related]
40. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
